Fondaparinux or Enoxaparin for Deep Venous Thrombosis?. Ann Intern Med. 2004;140:I-44. doi: 10.7326/0003-4819-140-11-200406010-00002
Download citation file:
Published: Ann Intern Med. 2004;140(11):I-44.
A blood clot inside the deep veins of the legs causes deep venous thrombosis (DVT). Pieces of the clot can break off, travel to the lungs, and cause serious and even fatal complications. Doctors usually give blood thinners to patients with DVT for several months to prevent pieces of clots from breaking loose and to stop new clots from forming. Vitamin K antagonists (warfarin, also known by the brand name Coumadin) are blood thinners that can be taken by mouth, but they take about a week to adequately thin blood and block clotting. Thus, patients with DVT must take other blood thinners during the first several days after a vitamin K antagonist is given. For many years, doctors initiated therapy for DVT with a blood-thinning drug known as unfractionated heparin. They gave this drug through a needle in a vein for a few days while patients started vitamin K antagonist therapy in the hospital. More recently, doctors have been using another preparation of heparin, low-molecular-weight heparin (LMWH), or drugs that selectively block clotting (factor Xa inhibitor). Both LMWH and factor Xa inhibitors can be injected under the skin, can be given at home, and do not require close monitoring of the dose. Several studies show that both drugs are safe and effective for treating DVT, but we do not know whether one is better than the other.
To see whether fondaparinux (factor Xa inhibitor) and enoxaparin (LMWH) have similar safety and efficacy for treating DVT.
2205 adults with symptomatic DVT from 154 centers worldwide.
The researchers randomly assigned 2205 patients with DVT to receive either fondaparinux once daily or enoxaparin twice daily. Both drugs were injected under the skin for at least 5 days. The patients and their doctors did not know who received which drug. All patients were also given blood thinner pills (vitamin K antagonists) for 3 months. During that time, doctors routinely checked for complications, such as bleeding, and also for evidence of new or repeated clots in the legs, lungs, or both.
About 1% of the patients in each group had a major bleeding complication during the first week or so of treatment. About 4% in each group had repeated clots within 3 months. About 3% to 4% in each group died during follow-up. Most of the deaths were due to causes other than the clots or bleeding.
Most patients received initial treatment in the hospital.
Fondaparinux and enoxaparin have similar safety and efficacy for initial treatment of patients with DVT.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only